PMID- 20720036
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20161125
IS  - 1535-5667 (Electronic)
IS  - 0161-5505 (Linking)
VI  - 51
IP  - 9
DP  - 2010 Sep
TI  - 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and 
      advanced Hodgkin lymphoma.
PG  - 1337-43
LID - 10.2967/jnumed.109.073197 [doi]
AB  - Our objective was to assess the prognostic value of (18)F-FDG PET after 2 cycles 
      of chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) 
      in Hodgkin lymphoma (HL) patients overall and in subgroups of patients with early 
      and advanced stages and with low and high risks according to the International 
      Prognostic Score (IPS). METHODS: One hundred fifteen patients with newly 
      diagnosed HL were prospectively included in the study. All underwent standard 
      ABVD therapy followed by consolidation radiotherapy in cases of bulky disease. 
      After 2 cycles of ABVD, the patients were evaluated with PET (PET2). Prognostic 
      analysis compared the 3-y event-free survival (EFS) rate to the PET2 results, 
      clinical data, and IPS. RESULTS: Of the 104 evaluated patients, 93 achieved 
      complete remission after first-line therapy. During a median follow-up of 36 mo, 
      relapse or disease progression was seen in 22 patients. Treatment failure was 
      seen in 16 of the 30 PET2-positive patients and in only 6 of the 74 PET2-negative 
      patients. PET2 was the only significant prognostic factor. The 3-y EFS was 53.4% 
      for PET2-positive patients and 90.5% for PET2-negative ones (P < 0.001). When 
      patients were categorized according to low or high IPS risk and according to 
      early or advanced stage of disease, PET2 was also significantly associated with 
      treatment outcome. CONCLUSION: PET2 is an accurate and independent predictor of 
      EFS in HL. A negative interim (18)F-FDG PET result is highly predictive of 
      treatment success in overall HL patients, as well as in subgroups with early or 
      advanced-stage disease and with low or high IPS risk.
FAU - Cerci, Juliano J
AU  - Cerci JJ
AD  - Department of Nuclear Medicine, Heart Institute (InCor), University of Sao Paulo 
      Medical School, Sao Paulo, Brazil. cercijuliano@hotmail.com
FAU - Pracchia, Luis F
AU  - Pracchia LF
FAU - Linardi, Camila C G
AU  - Linardi CC
FAU - Pitella, Felipe A
AU  - Pitella FA
FAU - Delbeke, Dominique
AU  - Delbeke D
FAU - Izaki, Marisa
AU  - Izaki M
FAU - Trindade, Evelinda
AU  - Trindade E
FAU - Soares, Jose Jr
AU  - Soares J Jr
FAU - Buccheri, Valeria
AU  - Buccheri V
FAU - Meneghetti, Jose C
AU  - Meneghetti JC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20100818
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
EIN - J Nucl Med. 2010 Oct;51(10):1658
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Bleomycin
MH  - Dacarbazine
MH  - Disease-Free Survival
MH  - Doxorubicin
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Hodgkin Disease/*diagnostic imaging/*drug therapy/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Positron-Emission Tomography
MH  - Prognosis
MH  - Vinblastine
MH  - Young Adult
EDAT- 2010/08/20 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/08/20 06:00
PHST- 2010/08/20 06:00 [entrez]
PHST- 2010/08/20 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - jnumed.109.073197 [pii]
AID - 10.2967/jnumed.109.073197 [doi]
PST - ppublish
SO  - J Nucl Med. 2010 Sep;51(9):1337-43. doi: 10.2967/jnumed.109.073197. Epub 2010 Aug 
      18.